Comparative Pharmacology
Head-to-head clinical analysis: RENOQUID versus SULFOSE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: RENOQUID versus SULFOSE.
RENOQUID vs SULFOSE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
RENOQUID is a combination of sulfamethoxazole, an intermediate-acting sulfonamide, and trimethoprim, a dihydrofolate reductase inhibitor. It inhibits sequential steps in bacterial folic acid synthesis: sulfamethoxazole inhibits dihydropteroate synthase, and trimethoprim inhibits dihydrofolate reductase, leading to bactericidal activity.
Sulfonamide antibiotic; inhibits bacterial dihydropteroate synthase, blocking folate synthesis and bacterial growth.
100 mg orally twice daily
Meningococcal meningitis: 100 mg/kg/day intravenously in 4 divided doses (maximum 6 g/day). For other infections: 2-4 g/day IV/IM in 3-4 divided doses.
None Documented
None Documented
Terminal elimination half-life is 2.5 hours (range 2–3 hours) in patients with normal renal function. In renal impairment (CrCl <30 mL/min), half-life may extend to 8–12 hours.
Terminal elimination half-life: 3-4 hours in patients with normal renal function; prolonged to 20-50 hours in severe renal impairment (CrCl <30 mL/min).
Renal excretion accounts for approximately 70% of elimination, with 30% excreted unchanged in urine. Biliary/fecal excretion accounts for 30%, primarily as metabolites.
Renal: ~90% as unchanged drug via glomerular filtration; biliary/fecal: <10%.
Category C
Category C
Sulfonamide Antibiotic
Sulfonamide Antibiotic